

(5.1%±2.7%) compared with control group (6.7%±3.2%) (P<0.01 VS P=0.04) at 10 mins after tirofiban infusion. The PMPs were also lower in intracoronary group than intravenous group (P=0.02). At 24 hours after tirofiban infusion, the PMPs of intracoronary and intravenous group was similar (P>0.05) and was significantly higher than control group (P=0.01 VS P=0.03). PMPs was similar at 12 after stopping tirofiban use among the 3 groups (P>0.05). Intracoronary group were superior to intravenous group and control group in terms of TIMI flow grade (P=0.03 VS P<0.01) and TIMI myocardial perfusion grade (P=0.02 VS P<0.01) immediately after PCI. MACEs rate in intracoronary group was lower than control group (P=0.03). And MACEs rate between intracoronary group and intravenous group, intravenous group and control group were similar (P>0.05, respectively). The incidence of bleeding events among 3 groups was similar.

Conclusions: Intracoronary tirofiban compared to the intravenous group, can effectively reduce the number of PMPs in patients with acute ST-segment elevation myocardial infarction undergoing emergency interventional treatment, achieve the purpose of the inhibition of activated platelets quickly, and reduce total MACEs events rate, but did not increase the risk of bleeding.

GW25-e0832

TNF receptor-associated factor 6 (TRAF6) mediates the angiotensin-induced non-canonical TGFβ pathway activation and differentiation of c-kit+ cardiac stem cells

Cao Qing, Shuyan Chen

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Objectives: TNF receptor-associated factor 6 (TRAF6) acts as a multifunctional regulator of the transforming growth factor (TGF)-β signaling pathway, and mediates Smad-independent JNK and p38 activation via TGF-β. This study was performed to test the hypothesis that TGF-β/TRAF6 is essential for angiotensin-II (Ang II)-induced differentiation of rat c-kit+ cardiac stem cells (CSCs).

Methods: c-kit+ CSCs were isolated from neonatal Sprague Dawley (SD) rats, and their c-kit status was confirmed with immunofluorescence staining. A TGF-β type I receptor inhibitor (SB431542) or the small interfering RNA (siRNA)-mediated knockdown of TRAF6 were used to investigate the role of TRAF6 in TGF-β signaling. Rescue of TRAF6 siRNA transfected cells with a 3'UTR deleted siRNA insensitive construct was conducted to rule out the off target effects of the siRNA. TRAF6 dominant negative (TRAF6DN) vector was constructed and used to infect c-kit+ CSCs, and western blotting was used to assess the expression of TRAF6, JNK, p38, cardiac-specific proteins, and Wnt signaling proteins. Physical interactions between TRAF6 and TGFβ receptors were studied by coimmunoprecipitation.

Results: Cardiac differentiation was suppressed in the absence of TRAF6. Forced expression of TRAF6 enhanced the expression of TGF-β-activated kinase1 (TAK1), and inhibited Wnt signaling. Furthermore, TRAF6 increased the expression of cardiac-specific proteins (cTnT and Cx-43) but inhibited the expression of Wnt3a.

Conclusions: Our data suggest that TRAF6 plays an important role in Ang II induced differentiation of c-kit+ CSCs via the non-canonical signaling pathway.

GW25-e1647

Effects of Herbal medicine Aconite Compound on Heart failure

Hou Xiujuan¹, Sun Wenyang², Li Geng³, Li Fangkai¹, Ma Junfu¹, Zhu Yuelan¹

¹Department of Rheumatology, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China, ²College of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China, ³Guangzhou University of Chinese Medicine, Guangzhou, China

Objectives: Herbal medicine, also known as Chinese medicine, plays a role in treatment of heart failure. Aconite, as one of Chinese medicine, is useful for treatment of heart failure. purpose of this study is to test efficacy of aconite compound in improving heart function from both clinical and animal study to provide reference for clinical application.

Methods: (1) Clinical study 41 Patients with chronic heart failure (CHF) were given treatment of Chinese medicine aconite compound (twice daily for 8 weeks). Before and after treatment, cardiac function (according to New York Heart Association NYHA classification method) and echocardiography (LVEF%) were observed; (2) Animal study SD rats (SPF, male, 240 - 280g), acute heart failure model was used as follows (isolated right carotid artery, heparin catheter was inserted through aortic valve into left ventricular cavity, intravenous injection of nimodipine (0.6 mg/kg), when left ventricular pressure maximal rate of rise (+LVdp/dtmax) decreased significantly, given treatment drugs, (Aconite compound dose as 7g/kg and duodenal administration, and Cedilanid 0.2mg/kg, femoral vein injection), continue tracings 1h, including before modeling, modeling immediately, after administration 10 mins, 20 mins, 30 mins, 40 mins, 50 mins, 60 mins to observe following indicators: left ventricular systolic pressure (LVSP mmHg), left ventricular end-diastolic pressure (LVEDP mmHg).

Results: (1) 21 patients were male (44.9%), 20 patients were female (55.1%), minimum age is 53 years, the maximum age is 95 years, mean age 73.88 ± 1.343 (years old), P=0.24>0.05, normal distribution; there was improvement of heart function according to before and after treatment echocardiography, the LVEF% Value was as follows: 44.71 ± 14.846 % VS 52.05 ± 14.854 %, t=-2.669, P=0.014<0.05; (2) Compared with normal group, LVEDP (-0.29 ± 0.57 vs 1.96 ± 0.99, P<0.05) were significantly higher, LVSP (105.37 ± 6.39 VS 129.00 ± 7.47, P<0.01) was significantly lower for acute

heart failure group. After femoral vein injection cedilanid 0.2mg/kg, compared with the model group, LVEDP decreased significantly (-0.74 ± 1.12 VS -0.53 ± 1.18), LVSP significantly higher (107.73 ± 7.49 VS 117.11 ± 7.16) after the treatment at 10mins, 118.00 ± 7.45 at 20 mins, 118.64 ± 7.44 at 30mins, 120.05 ± 8.25 at 40mins, 122.74 ± 8.80 at 50 mins, 125.04 ± 9.71 at 60mins), heart failure model copied successfully; Aconite compound 7g/kg were administered orally to acute heart failure rats, LVSP (105.37 ± 6.39 in model group vs 112.36 ± 5.83 at 10 mins, 115.69 ± 6.29 at 20mins, 117.21 ± 7.71 at 30mins, 118.34 ± 10.99 at 40mins, 120.08 ± 12.82 at 50mins, 123.96 ± 11.95 at 60mins), LVEDP (1.96 ± 0.99 VS 0.05 ± 0.87 at 10mins, -0.00 ± 0.99 at 20 mins, -0.06 ± 0.85 at 30mins, 0.02 ± 0.84 at 40mins, 0.14 ± 0.87 at 50mins, 0.13 ± 0.77 at 60 mins after the treatment) showed significant improvement (P<0.05; P<0.01).

Conclusions: Aconite compound can be used for the heart failure by improving heart function, and there is no significant side effects if it is used properly.

GW25-e4404

Cardiosphere and Cardiosphere-Derived Cells Can Be Derived from The Cadaver Autopsy

Wu Jian^{1,2}, Sun Yong^{1,2}, Tan Miao Xin^{1,2}, Chi Di^{1,2}, Zhang Maomao^{1,2}, Kang Kai^{2,3}, Liu Fang^{1,2}, Yu Bo^{1,2}, Wu Jian^{1,2}

¹Department of Cardiology, Second Affiliated Hospital of Harbin Medical University, ²(Harbin Medical University) The Key Laboratory of Myocardial Ischemia, Chinese Ministry of Education, ³Department of Cardiac Surgery, Second Affiliated Hospital of Harbin Medical University

Objectives: Currently, cardiosphere (CSP) and cardiosphere-derived cells (CDCs) are mainly obtained through myocardial biopsy and surgical, but there is limited access to tissue size, technical requirements and faced with infection, trauma and other problems. We assume that there is still a large number cardiac stem cell survival in the cadaver cardiac, we can get a sufficient amount of functional CSPs and CDCs through cadaver autopsy methods.

Methods: Mouse (C57BL/6) were sacrificed and placed in a refrigerator at 4 °C for 0 to 3 days, cardiac tissue was removed at different time points (D0, D1, D2, D3), cut into small pieces (approximately 1.5 cm³) and placed into dishes to culture explant-derived cells (EDCs) with complete explant medium. Flow cytometry analysis the expression of stem cell surface markers of EDCs such as CD117, CD133, CD105, Sca-1, CD90. EDCs were cultured with Cardiosphere growth medium to form CSP. CD105, CD117, GATA-4, Nkx2.5 and Connexin-43 were detected by immunofluorescence. CSP was placed in fibronectin covered flasks and grow into a layer of CDCs. Early cardiac transcription factors GATA-4, Nkx2.5 and Connexin-43 were detected by polymerase chain reaction (PCR), cardiac stem cell surface markers CD117 and Sca-1 were tested by flow cytometry. The proliferation ability was tested by cck-8, c-TnI and vWF were stained by immunofluorescence after induction of differentiation.

Results: Nine days after placing the cardiac tissue in dishes, EDCs from mouse cadaver cardiac were successfully isolated and cultured. Each group of EDCs are rich in stem cell surface markers expressing such as CD117, CD133, CD105, Sca-1, CD90, and could culture into CSP and CDCs. With the extension of the dead days, the number of EDCs was able to harvest from the autopsy gradually decreased, the amount of EDCs could harvest at D3 decreased significantly (the number of each 60 mm dishes at D0, D1, D2, D3 were 86.00 ± 5.27 × 10⁴, 66.92 ± 3.15 × 10⁴, 49.67 ± 3.17 × 10⁴, 23.75 ± 1.52 × 10⁴, respectively). There is no significant differences in CD117 and Sca-1 expression at D0 and D1 in EDCs and CDCs, but decreased at D2 and D3. No significant difference was found in the ability of EDCs to form CSPs (the number of each well of 24-well plate at D0, D1, D2, D3 were 38.33 ± 1.25, 38.00 ± 2.45, 37.33 ± 1.25, 38.00 ± 2.16, respectively), and each group of CSPs was positive expression CD117, CD105, GATA-4, NKX2.5 and Connexin-43. CDCs obtained from cadaver autopsy both express GATA-4, Nkx2.5 and Connexin-43 when detected by PCR and immunofluorescence, but decreased in D2 and D3. There is no significant difference in proliferation when detect by cck-8 and c-TnI, vWF expression after induction of CDCs.

Conclusions: There is a variety of stem cells survival in cadaveric cardiac even at three days post-mortem. EDCs harvested through cadaver autopsy methods can form enough CSPs and CDCs. CDCs from cadaver autopsy also have strong ability of proliferation and differentiation. CSPs and CDCs obtained from cadaver autopsy may be used as a source or alternative sources of allograft transplantation and needs further research in vivo, which may solve the insufficient source problems existing in cardiac stem cells.

GW25-e4537

Statin effects on UA patients microRNA expression profile and regulatory functional network analysis

Li Jingjin, Chongyou Lee, Feng Zhang, Jingyi Ren, Hong Chen
Peking university people's hospital

Objectives: Unstable angina (UA), an acute coronary syndrome caused by disruption of atherosclerotic plaque triggered thrombosis. The blood vessel narrow and reduction of blood flow induce the symptom. Statin therapy benefits UA patients by cholesterol independent effect. Yet the mechanism of statin pleiotropic effect remained to be study. MicroRNAs (miRNAs), small non-coding RNAs, are post-transcriptional regulators of gene expression. In this study we aim to investigate statins' novel mechanism mediated by miRNAs. Moreover we carry out systematic analysis of the miRNAs functional networks in atherosclerotic lesions.